Harold Hamm Diabetes Center Grant Opportunities

Opportunities for Harold Hamm Diabetes Center members include funding awards and access to core facilities. A variety of funding awards is available to members to encourage the further development of their work. Award applications are evaluated on a competitive, peer-reviewed basis by the Harold Hamm Research Grants Committee. Additional awards, such as matching awards to other funding opportunities, will be announced if they become available.

Spring 2021 Award Opportunities

Funding Opportunity Summary

The Harold Hamm Diabetes Center (HHDC) is pleased to announce pilot funding opportunities for 2021. The HHDC Pilot Program will consider funding three types of proposals including Team Science proposals, Seed projects, and Equipment grants. Through matching funds from HHDC and PHF this program will award up to $1.6M to researchers to launch investigations for Diabetes-Research. Additionally, this year HHDC is collaborating with the Stephenson Cancer Center (SCC) to offer $1.0M to researchers to launch collaborative investigations for Diabetes and Cancer Research. This program will consider two types of proposals including Team Science proposals for established teams and Pre-Team Science proposals for teams that are just forming.

Key Information

HHDC-PHF Funded Programs:

  • Team Science Grant: $100,000 per year up to 3 years
  • Seed Grant: $50,000 for 1 year
  • Equipment Grant: up to $250,000

HHDC-SCC Funded Programs:

  • Team Science Grant: $100,000 per year up to 3 years
  • Pre-Team Science Grant: $25,000 for 1 year

Funding Priorities

Applications that address the themes of the HHDC will be given higher priority. Each proposal must address one or more of the following themes that describe HHDC funding priorities:

  • Theme 1: Developmental programming and disease pathways across the lifespan, especially in the first 1000 days that accelerate development of obesity, diabetes, and cancer.
  • Theme 2: Environmental and genetic influences on the health of the pancreatic β cell.
  • Theme 3: Co-morbidities related to diabetes/obesity and cancer; basic or epidemiological studies.
  • Theme 4: Clinical care-outcomes /novel therapeutics for diabetes- including QI or AI (machine learning) initiatives or novel approaches to health care disparities for underserved populations in Oklahoma.

Covid-19 related proposals: Proposals studying Covid-19 are welcome if they are related to the HHDC mission, e.g. exploring the relationship between diabetes and Covid-19 presentation or outcomes, and there is a plan for follow-on studies by applying for extramural funding.

Application Process

Letter of Intent

A Letter of intent due to HHDCGrants@ouhsc.edu by 5PM January 15, 2021. Applications selected for full application submission will be requested by February 1, 2021.

Full Application

Applicants selected for further review will be invited to submit a full application DUE to HHDCGrants@ouhsc.edu by 5PM, March 15, 2021 to be reviewed and considered as a part of the HHDC-PHF Diabetes Grant Program or the HHDC Diabetes – Cancer Program. The projected start date for the award will be July 1, 2021.

Applicants not selected to be part of the HHDC-PHF Diabetes Grant Program may submit their applications through the regular PHF grant submission process.

Program Application and Guidelines

All applications will follow the PHF Application Form, Terms and Guidelines found here:

PHF – HHDC Diabetes Programs:

SCC-HHDC Diabetes/Cancer Programs:


For Administration questions or for special exception of the announcement approval, please contact Katie Hoefling at HHDCGrants@ouhsc.edu. For scientific matters contact Dr. Friedman, jed-friedman@ouhsc.edu.

For more information or questions, please e-mail hhdcmembership@ouhsc.edu, or contact Katie Hoefling at
man and girl painting a wall
Explore Supportive Care services for your cancer journey Learn More
Find out how you may qualify to enroll in a cancer clinical trial Learn More
Find out if you’re at risk for diabetes Learn More
See what our commitment to ending diabetes in this century means for you Learn More